2-(Azetidin-3-yl)-5-bromopyridine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(Azetidin-3-yl)-5-bromopyridine
• 英文别名: 2-(azetidin-3-yl)-5-bromopyridine
• 化学式: C₈H₉BrN₂
• mdl: MFCD17480650
• 分子量: 213.07
• InChiKey: VVAWGZDWSPQMKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS<br/>[FR] COMPOSÉS AZÉTIDINYLES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE GLYT1
  申请人：DART NEUROSCIENCE LLC

  公开号：WO2016073420A1

  公开（公告）日：2016-05-12

  The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyTl activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.

  该发明提供了一种化学实体的公式(I)，其中R1、R2、R3、R4、X和Y具有本文所述的任何值，以及包含这种化学实体的组合物；制备它们的方法；以及它们在广泛的方法中的应用，包括代谢和反应动力学研究；检测和成像技术；放射性治疗；调节和治疗由GlyT1活性介导的疾病；治疗神经系统疾病、中枢神经系统疾病、痴呆、神经退行性疾病和受创功能丧失；治疗中风，包括中风康复期间的认知和运动缺陷；促进神经保护和神经恢复；增强认知和运动训练的效率，包括动物技能训练；以及治疗其他疾病，包括疼痛和酒精依赖症。
• Substituted azetidinyl compounds as GlyT1 inhibitors
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US10040759B2

  公开（公告）日：2018-08-07

  The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.

  本发明提供了式(I)的化学实体，其中 R1、R2、R3、R4、X 和 Y 具有本文所述的任一值，还提供了包含这种化学实体的组合物；制造它们的方法；以及它们在多种方法中的用途，包括代谢和反应动力学研究；检测和成像技术；放射性治疗；调节和治疗由 GlyT1 活性介导的疾病；治疗神经系统疾病、中枢神经系统疾病、痴呆症、神经退行性疾病和创伤依赖性功能丧失；治疗中风，包括中风康复期间的认知和运动障碍；促进神经保护和神经恢复；提高认知和运动训练的效率，包括动物技能训练；以及治疗其他疾病，包括疼痛和酒精依赖。
• SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS
  申请人：Dart NeuroScience (Cayman) Ltd.

  公开号：EP3215500A1

  公开（公告）日：2017-09-13